Keywords: USA, FTC, Lundbeck, NeoProfen, Eli Lilly, Zyprexa, Overpricing, Class action
In USA, Lundbeck wins Federal Trade Commission case over NeoProfen; Lilly wins Court action on Zyprexa
Article | 13 September 2010
The US Federal District Court has ruled in favor of Danish drugmaker H Lundbeck (LUND: DC) and found no violation ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
